Salvage therapy with single agent bendamustine for recurrent glioblastoma

Chamberlain, Marc; Johnston, Sandra
December 2011
Journal of Neuro-Oncology;Dec2011, Vol. 105 Issue 3, p523
Academic Journal
The treatment of recurrent glioblastoma (GBM) remains challenging notwithstanding the recent approval of bevacizumab for this indication. Bendamustine has a bifunctional mechanism of action including alkylation, penetrates the CNS and does not show cross resistance to other alkylator chemotherapies. In a single institution phase 2 trial, patients with recurrent GBM were treated with bendamustine (100 mg/m/day administered intravenously for two consecutive days every 4 weeks). The primary study endpoint was 6-month progression free survival (PFS-6). An interim analysis for futility was conducted according to a Simon two-stage minimax design. Complete blood counts were obtained bimonthly, clinical evaluations and brain imaging every month for the first cycle and bimonthly thereafter. Treatment responses were based upon MacDonald criteria. Sixteen patients were enrolled (nine men; seven women), with a median age of 53 years (range 36-68) and a median Karnofsky performance status of 90 (range 70-100). Nine patients were treated at first relapse and seven at second relapse (five patients were bevacizumab failures). A total of 25 cycles of bendamustine were administered with a median of 1 (range 1-6). Bendamustine-related toxicity was seen in eight patients; lymphopenia in seven (5 grade 3; 2 Grade 4), thrombocytopenia in two (1 Grade 3; 1 Grade 4), and neutropenia in one (1 Grade 3). Fourteen patients have died due to disease progression, two patients are alive and on alternative therapies. Only one patient was progression-free at 6 months, triggering the stopping rule for futility. Bendamustine was reasonably well tolerated but failed to meet the study criteria for activity in adults with recurrent GBM.


Related Articles

  • The Role of Integrins in Glioma Biology and Anti-Glioma Therapies. Tabatabai, Ghazaleh; Tonn, Jörg-Christian; Stupp, Roger; Weller, Michael // Current Pharmaceutical Design;8/1/2011, Vol. 17 Issue 23, p2402 

    The tumor environment is critical for tumor maintenance and progression. Integrins are a large family of cell surface receptors mediating the interaction of tumor cells with their microenvironment and play important roles in glioma biology, including migration, invasion, angiogenesis and tumor...

  • Neuro-oncology.  // Annals of Oncology;Oct2010 Supplement 8, Vol. 21 Issue suppl_8, pviii329 

    No abstract available.

  • Bevacizumab for Glioblastoma--A Promising Drug or Not? Motoo Nagane; Ryo Nishikawa // Cancers;Dec2013, Vol. 5 Issue 4, p1456 

    Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS's were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence,...

  • Post progression survival in glioblastoma: where are we? Franceschi, Enrico; Ermani, Mario; Bartolini, Stefania; Bartolotti, Marco; Poggi, Rosalba; Tallini, Giovanni; Marucci, Gianluca; Fioravanti, Antonio; Tosoni, Alicia; Agati, Raffaele; Bacci, Antonella; Pozzati, Eugenio; Morandi, Luca; Balestrini, Damiano; Ghimenton, Claudio; Crisi, Girolamo; Brandes, Alba // Journal of Neuro-Oncology;Jan2015, Vol. 121 Issue 2, p399 

    The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of...

  • P-0094 HEPATIC ARTERIAL INFUSION OF CHEMOTHERAPY AS A SALVAGE THERAPY FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. Yu-Yun, Shao; Po-Chin, Liang; Yao-Ming, Wu; Chun-Chieh, Huang; Kai-Wen, Huang; Chia-Hsien, Cheng Jason; Chih-Hung, Hsu; Chiun, Hsu; Ann-Lii, Cheng; Zhong-Zhe, Lin // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii42 

    No abstract available.

  • Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial. Shingo Takano; Eiichi Ishikawa; Kei Nakai; Masahide Matsuda; Tomohiko Masumoto; Tetsuya Yamamoto; Akira Matsumura // OncoTargets & Therapy;2014, Vol. 7, p1551 

    An antiangiogenic approach is especially suitable for the treatment of malignant gliomas. Recently, two large clinical trials in newly diagnosed glioblastoma (the Avastin in Glioblastoma study and Radiation Therapy Oncology Group 0825 study) showed a 3- to 4-month prolongation of...

  • Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Loupakis, Fotios; Bria, Emilio; Vaccaro, Vanja; Cuppone, Federica; Milella, Michele; Carlini, Paolo; Cremolini, Chiara; Salvatore, Lisa; Falcone, Alfredo; Muti, Paola; Sperduti, Isabella; Giannarelli, Diana; Cognetti, Francesco // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p58 

    Background: Although the addition of bevacizumab to 1st line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated. Methods: A literature-based meta-analysis was conducted;...

  • Salvage or savage chemotherapy for poor-risk or relapsed testis cancer—20 years later, not much has changed. Raghavan, D. // Annals of Oncology;Apr2012, Vol. 23 Issue 4, p813 

    No abstract available.

  • Complete Response To FOLFOX4 Therapy In A Patient With Advanced Urothelial Cancer: A Case Report. Seo, Yu Ri; Kim, Se Hyung; Kim, Hyun Jung; Kim, Chan Kyu; Park, Seong Kyu; Koh, Eun Suk; Hong, Dae Sik // Asia-Pacific Journal of Oncological Medicine;2010, Vol. 2 Issue 1, p86 

    No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics